CRDF Q2 2024 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$163,000+50.9% YoY

Gross Profit

$58,00035.6% margin

Operating Income

-$13M-7696.3% margin

Net Income

-$12M-7225.8% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-20.5%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$66M

Total Liabilities

$14M

Stockholders' Equity

$52M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$163,000	$108,000	+50.9%
Gross Profit	$58,000	$108,000	-46.3%
Operating Income	-$13M	-$12M	-2.8%
Net Income	-$12M	-$11M	-5.6%